Electra Therapeutics Files for US IPO

08:44 AM EDT, 09/14/2026 (MT Newswires) -- Electra Therapeutics has filed a preliminary prospectus with the US Securities and Exchange Commission for an initial public offering of about 21.7 million common shares priced between $14 and $16 apiece. Underwriters have been granted a 30-day period to purchase an additional 3.3 million shares, according to the clinical-stage biopharmaceutical company. Electra Therapeutics said it expects to receive net proceeds of about $296.6 million, assuming the midpoint of the stock price range set, which will be applied to advance the development of ipsoprubart in secondary hemophagocytic lymphohistiocytosis, among others. The company has applied to list its stock on the Nasdaq Global Select Market under the symbol "ETRA," as per the filing.